Article Information
History
- August 9, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Neilshan Loedy1,*,#,
- Hector G Dorta2,*,
- Steven Abrams1,3,
- Jonas Crèvecoeur1,
- Daniel R. Morales2,
- Catherine Cohet2,
- Lander Willem4,5,
- Geert Molenberghs1,6,
- Niel Hens1,4,
- Xavier Kurz2,
- Chantal Quinten2,** and
- Johan Verbeeck1,**
- 1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
- 2European Medicines Agency, Amsterdam, The Netherlands
- 3Global Health Institute (GHI), Family Medicine and Population Health, University of Antwerp, Antwerp, Belgium
- 4Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium
- 5Primary and interdisciplinary care (ELIZA), Family Medicine and Population Health, University of Antwerp, Antwerp, Belgium
- 6I-Biostat, KU Leuven, Leuven, Belgium
- ↵#Corresponding author; email: neilshan.loedy{at}uhasselt.be
Posted August 09, 2024.
An extension of the Benefit Risk Assessment of VaccinEs (BRAVE) Toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union
